Búsqueda Imágenes Maps Play YouTube Noticias Gmail Drive Más »
Iniciar sesión
Usuarios de lectores de pantalla: deben hacer clic en este enlace para utilizar el modo de accesibilidad. Este modo tiene las mismas funciones esenciales pero funciona mejor con el lector.

Patentes

  1. Búsqueda avanzada de patentes
Número de publicaciónUS3384541 A
Tipo de publicaciónConcesión
Fecha de publicación21 May 1968
Fecha de presentación28 Oct 1964
Fecha de prioridad28 Oct 1964
Número de publicaciónUS 3384541 A, US 3384541A, US-A-3384541, US3384541 A, US3384541A
InventoresWilliam G Clark
Cesionario originalWilliam G. Clark
Exportar citaBiBTeX, EndNote, RefMan
Enlaces externos: USPTO, Cesión de USPTO, Espacenet
Spermicidal vaginal pharmaceutical concentrate for producing nonaqueous foam with aerosol propellants
US 3384541 A
Resumen  disponible en
Imágenes(4)
Previous page
Next page
Reclamaciones  disponible en
Descripción  (El texto procesado por OCR puede contener errores)

United States Patent 3,384,541 SPERMICIDAL VAGINAL PHARMACEUTICAL CONCENTRATE FOR PRODUCENG NON- AQUEOUS FOAM WITH AEROSOL PROPEL- LANTS William G. Clark, 1142 Las Pulgas Road, Pacific Palisades, Calif. 90272 No Drawing. Filed Oct. 28, 1964, Ser. No. 407,231 1 Claim. (Cl. 167-58) ABSTRACT OF THE DISCLOSURE The invention provides a new composition of matter comprising a major proportion of propylene glycol in a minor proportion of an ethoxylated tallow alcohol, the composition being adapted to incorporation in foam-producing assemblies.

This invention relates to a new and useful non-aqueous foam-producing pharmaceutical substance, and more particularly to such a substance adapted for use as a medicant in a self-propelled dispenser using fluorinated hydrocarbons or other aerosol propellants.

There is a need for a simple, easily used single-dose contraceptive which can be applied as an aerosol foam into the vaginal canal. There has also been a need for a pharmaceutical vehicle for medicants adapted to be injected into human body cavities that can be used either with or without water, depending upon the stability of the ingredients to be incorporated into the preparation. Thus, it is desirable to have a single base that can be used with various enzymes, antibiotics, and medicinal agents, with or without spermicidal agents.

Accordingly, it is a primary object of the present invention to provide a newand useful non-aqueous foamproducing vehicle.

Another object of the invention is to provide a vehicle of the type described in combination with spermicidal substances.

Another object of the present invention is to provide a foam-producing vehicle that can be used either with or without water and various enzymes, antibiotics, and spermicidal agents.

Yet another object .of the present invention is to provide a new and useful non-aqueous foam-producing vehicle which contains ethoxylated tallow alcohol as a foaming agent, emulsifier, detergent, Wetting agent, and viscosity builder.

A further object of the present invention is to provide a vehicle of the type described which is also spermicidal.

A still further object of the present invention is to provide a vehicle of the type described which is especially suited for use in and in combination with aerosol type applicators for injecting medicants into human body cavities.

A medicinal application of this type is shown and claimed in copending application Ser. No. 407,170, filed Oct. 28, 1964, by the instant inventor, now abandoned.

The non-aqueous foam-producing pharmaceutical substance of the present invention includes a vehicle containing ethoxylated tallow alcohol as a foaming agent, emulsifier, detergent, wetting agent, and viscosity builder. The

3,384,541 Patented May 21, 1968 "ice ethoxylated alcohol is a condensate of pressure-hydrogenated tallow alcohol. The general formula is with R being a combination of CH (CH CH OH (stearyl alcohol 62%), CH (CH CH OH (cetyl alcohol 33%), and CH (CH CH OH (myristyl alcohol 5%) and the x ranging from three to eleven moles of ethylene oxide.

Propylene glycol U.S.P. may serve as a solvent, preservative, and emollient, and propylhydroxyparaben U.S.P. and methylhydroxyparaben U.S.P. are used as preservatives. In preparing the vehicle, grams of propylene glycol U.S.P'. are heated to approximately 50 degrees C. and 0.4 gram of methylhydroxyparaben plus 0.2 grain of propylhydroxyparaben are added and stirred. Two grams of ethoxylated tallow alcohol containing three moles of ethylene oxide, oil-soluble type, are heated to 50 degrees C., and combined with the propylene glycol preservative combination. Ethoxylated tallow alcohol containing from three to eleven moles of ethylene oxide may be used in this formula, depending upon the consistency of foam desired. The product is allowed to cool, and a sufficient amount of propylene glycol U.S.P. is added to make the product weigh 50 grams. Other glycols, as well as glycerol can be used in place of propylene glycol.

Spermicidal preparations are made from this vehicle, as described in the following examples, by dissolving the active ingredients in a sufiicient amount of propylene glycol U.S.P. to make 50 grams, and the resulting product is combined with 50 grams of the vehicle to make grams of spermicidal foam concentrate. In some cases, heat must be employed to effect solution. Heat labile substances must be added after cooling.

The non-ionic nature of the vehicle makes possible the addition of cationic or anionic substances without affecting the foam-producing and barrier action of the ingredients. Propylene glycol is an excellent solvent for many organic chemicals. Its solubility with water in all proportions makes possible the addition of aqueous solutions of spermicidal agents. This vehicle mixes quickly with seminal fluid and vaginal secretions, permitting rapid action of the active ingredients. Its surfactant action spreads the spermicide into all surfaces and crevices. The non-aqueous nature of the vehicle minimizes variations in action due to individual variations of moisture present. The viscous base and foam provide barrier action to passage of sperm through the cervix.

The vehicle itself is spermicidal as shown by the Sanderson-Cramer method of spermicidal evaluation. The vehicle, when diluted with two parts of buffered fructose solution, kills human sperm in twenty seconds. The buffered fructose solution contained three percent fructose, 0.24% anhydrous phosphate, 0.01% mono potassium phosphate, 0.2% sodium chloride, and distilled water (q.s.).

When diluted with an equal volume of propylene glycol U.S.P., the vehicle of the present invention produces a foam with propellants from an aerosol container of the types shown and described in said copending application. A partial emulsification results when the foam concentrate is shaken with fluorinated hydrocarbons or other aerosol propellants. When released in the manner described in said copending application, an excellent foam is produced. The ratio of vehicle to added propylene glycol can be altered to vary the foam consistency or to compensate for viscosities of added substances. Because of the insolubility of the ethoxylated tallow alcohols in water, the latter can be added to stiffen the foam where it does not affect the stability of added substances.

The formulation has been shown to be non-toxic to the mucosa of the human vagina and cervix. An amount in excess of that ordinarily used, namely grams of the liquid foam concentrate, was applied to the cervical mucosa of six oflice patients and examination made the next morning. No indications of inflammation were seen, even on repeated application.

The vehicle of the present invention is stable over long periods of time and maintains the stability of added ingredients which are unstable in aqueous vehicles of the prior art.

The following are typical examples of the non-aqueous foam-producing pharmaceutical substance of the present invention:

EXAMPLE 1 EXAMPLE 2 The product of Example 1 was prepared in the manner of Example 1 except that the ethoxylated tallow alcohol contained four moles of ethylene oxide.

EXAMPLE 3 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained five moles of ethylene oxide.

EXAMPLE 4 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained six moles of ethylene oxide.

EXAMPLE 5 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained seven moles of ethylene oxide.

EXAMPLE 6 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained eight moles of ethylene oxide.

EXAMPLE 7 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained nine moles of ethylene oxide.

EXAMPLE 8 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained ten moles of ethylene oxide.

EXAMPLE 9 The produce of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained eleven moles of ethylene oxide.

EXAMPLE 10 A product was prepared in accordance with each of the preceding examples except that, in each case, eighty grams 1 of glycerol USP were used in place of the propylene glycol.

EXAMPLE 11 Grams Aliphatic polyoxyethylene ether (100% active.

Made from commercial tridecyl alcohol and ethylene oxide to give material with an inverse cloud point of approximately 40-42 C. The material is made by standard ethoxylation technique) 5 The vehicle of Example 1 50 Propylene glycol q.s. ad 100 The aliphatic polyoxyethylene ether provides an excellent spermicide. Its non-ionic nature permits its combination with anionic or cationic agents without any change in spermicidal or antibiotic power. This composition produces an excellent foam when combined with propellants in aerosol containers. The ratio of propylene glycol to vehicle can be altered to produce varied consistency of foam.

EXAMPLE 12 Grams Aliphatic polyoxyethylene ether (100% active, de-

scribed in Example 11) 5 Lactic acid U.S.P. 0.5 Distilled water 10 Vehicle of Example 1 50 Propylene glycol U.S.P. q.s. ad

Sufiicient acid has been added to this product to produce a pH of 4.0 which increases the spermicidal power because it produces a condition resembling the vaginal pH of 4.5. Water has been added to aid in the ionization of the acid because the effect of acids in spermicides depends upon the extent to which they ionize.

EXAMPLE 13 Grams Aliphatic polyoxyethylene ether (100% active, de-

scribed in Example 11) 5 Papain 1 Vehicle of Example 2 50 Propylene glycol U.S.P. q.s. ad 100 EXAMPLE 14 Grams Aliphatic polyoxyethylene ether (100 active, de-

scribed in Example 11) 5 Trypsin 1 Vehicle of Example 3 50 Propylene glycol U.S.P. q.s. ad 100 Other pancreatic enzymes that could be used in the foam concentrate include cathepsins and chymotrypsin.

EXAMPLE l5 Grams Aliphatic polyoxyethylene ether of Example 11 5 Desoxyribonucleases (a Dornase proteolytic enzyme) 1 Vehicle of Example 4 50 Propylene glycol U.S.P. q.s. ad 100 Bacterial protease from B. Subtz'lis 1 Vehicle of Example 5 50 Propylene glycol U.S.P. q.s. ad 100 Other proteases from microbiological sources included those from Pseudomonas, Clostridia, and fungi. Hyaluronidase also has been used. The proteolytic enzymes described in Examples 13 through 16 enhance the mucolytic action upon sperm as well as vaginal and cervical mucous, allowing the spermicide to reach the sperm better. The cleansing and anti-inflammatory, antibioticenhancing, fibrinolytic, mucolytic, and debriding properties of such enzymes is known. Thus, they can be used in vehicles of the present invention for intravaginal infestations such as vaginitis, leukorrhea, trichomonas, moniliasis, as well as for hygienic and prophylactic purposes by incorporating them alone or in combination with suitable antiseptics, germicides, antibiotics, and peptizing agents such as carbamide. Water has been omitted in Examples 13 through 16 to increase the stability of the enzymes and antibiotics. Stability studies have shown that enzymes retain over 50% of their proteolytic activity against standard substrates when left at room temperature for six months.

Propylene glycol U.S.P. q.s. ad 100 This combination was formulated for instances where a contraceptive is desired in combination with trichomonal or other antibiotic or where the latter is desired alone in an aerosol foam treatment. It is known that Tyrothricin and Chlortetracycline are more active protozoal agents than streptomycin, chloramphenicol, or penicillin. Tyrothricin possesses many advantages over other antibiotics for use in the vehicle of the present invention. It is odorless and has remarkable stability, being stable in aqueous solutions and propylene glycol for long periods even at summer temperatures. Its solution in propylene glycol may be autoclaved without significant loss of activity. Its solubility in propylene glycol and its compatibility with many organic and inorganic substances makes it uniquely useful with a spermicidal composition. Lactic acid has been added to this composition to maintain a healthier flora in the vagina. As is known, the treatment of trichomonas vaginalis is directed toward cleanliness and maintenance of acid pH in the vagina. Water has been added to the formula to aid in the ionization of the acid.

EXAMPLE l8 Grams Aliphatic polyoxyethylene ether of Example 11 5 Tyrothricin 0.5 Papain 1 Vehicle of Example 7 50 Propylene glycol q.s. ad 100 can be expected in vivo that do not show in this test because of the enhanced action of the added enzymes and acids. No appreciable difference in spermicidal action was noted with the addition of antibiotics in vitro.

EXAMPLE 19 Grams Aliphatic polyoxyethylene ether of Example 11 5 Hydrocortisone alcohol, micronized 1 Vehicle of Example 8 50 Propylene glycol q.s. ad

Hydrocortisone can be used along with the contraceptive when its anti-inflammatory action is desired. The relative insolubility and its high degree of activity of the alcohol form make it useful, especially where the systemic effects of the glucocorticoid are not desired.

EXAMPLE 20 Grams Aliphatic polyoxyethylene ether of Example 1 5 Hydrocortisone alcohol, micronized 1 Neomycin sulfate, micronized 0.5 Vehicle of Example 1 50 Glycerol q.s. ad 100 This formula combines the anti-inflammatory qualities of Hydrocortisone with the anti-pyogenic action of neomycin plus contraceptive.

EXAMPLE 21 Grams Aliphatic polyoxyethylene ether of Example 11 5 Sulfanilamide, micronized 10 Vehicle of Example 1 50 Propylene glycol q.s. ad 100 Other sulfonamides may be used in place of the sulfanilamide or a combination of two or more may be used. This formula is useful in the post-operative care of the cervix and for secondary invasions of trichomonas vaginalis.

EXAMPLE 22 Grams Aliphatic polyoxyethylene ether of Example 11 5 Sulfanilamide, micronized 10 Neomycin sulfate, micronized 0.5 Vehicle of Example 1 50 Propylene glycol U.S.P. q.s.d. ad 100 This formula can be used when the action of a sulfonamide along with an antibiotic is desired plus contraceptive. Another sulfonamide or sulfonamides may be used as well as antibiotics.

EXAMPLE 23 Grams Aliphatic polyoxyethylene ether of Example 11 5 Povidone iodine NND 1 Vehicle of Example 1 50 Propylene glycol q.s. ad 100 The addition of the iodine compound aids in the treatment of non-specific vaginitis and Candida albicans, Monilia, and T richomonas vaginalis along with a contraceptive.

EXAMPLE 24 Examples were prepared in accordance with each of the thirteen preceding examples (ll-23) execept that in each case the aliphatic polyoxyethylene ether was omitted.

While the particular embodiments of the present invention herein described in detail are fully capable of attaining the objects and providing the advantages hereinbefore stated, it is to be understood that they are merely illustrative of the presently preferred embodiments of the invention and that no limitations are intended to the specific embodiments herein described other than as defined in the appended claim.

I claim:

1. A spermicidal vaginal pharmaceutical concentrate for producing non-aqueous foam with aerosol propellants comprising:

80 grams of propylene glycol;

0.4 gram of methylhydroxyparaben;

0.2 gram of propylhydroxyparaben; I

2 grams of ethoxylated tallow alcohol containing from three to eleven moles of ethylene oxide of the oilsoluble type; said composition of matter being nonaqueous, thereby constituting a stable vehicle for proteolytic enzymes and antibiotics.

References Cited UNITED STATES PATENTS 2,854,377 9/1958 Elias 16758 2,943,979 7/1960 Elias 167-58 3,055,834 9/1962 Charle et a1. 25290 8 3,131,152 4/1964 Klausner 252-305 3,219,525 11/1965 Berkow 167-58 3,240,396 3/ 1966 Friedenberg 222-146 3,244,589 4/ 1966 Sunnen et a1 167-58 OTHER REFERENCES McCutcheon, John W.: D & E, 1963, Detergents and Emulsifiers, 1963, Annual pub., 1963, Morristown, N.J., pp.: cover, inside front cover, 31, 33, 45, 57, 58, 62, 63, 86, 87, 112, 116, 131, 135.

Federal Register 30 (228): 14639 Nov. 25, 1965, Dimethyl Sulfoxide (DMSO) Preparations, Termination of Clinical Testing and Investigational Use.

Ferm: Teratogenic Efiect of Dimethyl Sulphoxide, Lancet, I, 1966, pp. 208-209, Jan. 22, 1966.

LEWIS GOTTS, Primary Examiner.

SHEP K. ROSE, Examiner.

Citas de patentes
Patente citada Fecha de presentación Fecha de publicación Solicitante Título
US2854377 *22 Sep 195530 Sep 1958Nathaniel M EliasEffervescent compositions containing a surface active agent
US2943979 *23 Jun 19595 Jul 1960Nathaniel M EliasConcentrated foam-producing spermicides
US3055834 *2 Jun 195825 Sep 1962OrealAnhydrous anion-active detergents in the form of aerosols
US3131152 *13 Jun 196028 Abr 1964Allied ChemFoam producing formulations
US3219525 *16 Ene 196323 Nov 1965Menlo Park Lab IncVaginal douche solution
US3240396 *11 Jun 196315 Mar 1966Robert M FriedenbergAerosol dispenser
US3244589 *26 Oct 19625 Abr 1966SunnenAlkyl phenoxy polyethoxy ether spermicidal aerosol
Citada por
Patente citante Fecha de presentación Fecha de publicación Solicitante Título
US3819528 *6 Mar 197225 Jun 1974Procter & GambleStabilized aqueous enzyme compositions
US3929985 *18 Ene 197430 Dic 1975Richardson Merrell IncAnhydrous candicidin foam compositions
US4252787 *27 Dic 197624 Feb 1981Cambridge Research And Development GroupAnti-fertility composition and method
US4310510 *3 Oct 198012 Ene 1982Sherman Kenneth NSelf administrable anti-fertility composition
US4551148 *11 Oct 19845 Nov 1985Kv Pharmaceutical CompanyVaginal delivery systems and their methods of preparation and use
US5266329 *31 Oct 198530 Nov 1993Kv Pharmaceutical CompanyVaginal delivery system
US5340836 *1 Jun 199223 Ago 1994Mark S. ReinhardComposition and method for treatment of vaginal yeast infections
US5573765 *13 Ago 199412 Nov 1996Mark S. ReinhardComposition and method for treatment of vaginal yeast infections
US770007620 Ago 200420 Abr 2010Foamix, Ltd.Penetrating pharmaceutical foam
US77045189 May 200627 Abr 2010Foamix, Ltd.Foamable vehicle and pharmaceutical compositions thereof
US782014528 Abr 200426 Oct 2010Foamix Ltd.Oleaginous pharmaceutical and cosmetic foam
US811438526 Dic 200614 Feb 2012Foamix Ltd.Oleaginous pharmaceutical and cosmetic foam
US81191068 Jul 200921 Feb 2012Foamix LtdFoamable iodine compositions
US811910913 Mar 200721 Feb 2012Foamix Ltd.Foamable compositions, kits and methods for hyperhidrosis
US81191506 Jul 200621 Feb 2012Foamix Ltd.Non-flammable insecticide composition and uses thereof
US83439457 Jun 20101 Ene 2013Foamix Ltd.Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US836209126 Abr 201029 Ene 2013Foamix Ltd.Foamable vehicle and pharmaceutical compositions thereof
US84354981 Abr 20107 May 2013Foamix Ltd.Penetrating pharmaceutical foam
US848637414 Ene 200816 Jul 2013Foamix Ltd.Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US848637520 Feb 201216 Jul 2013Foamix Ltd.Foamable compositions
US84863766 Abr 200516 Jul 2013Foamix Ltd.Moisturizing foam containing lanolin
US851271812 Feb 201020 Ago 2013Foamix Ltd.Pharmaceutical composition for topical application
US85183766 Oct 200927 Ago 2013Foamix Ltd.Oil-based foamable carriers and formulations
US851837814 Sep 201027 Ago 2013Foamix Ltd.Oleaginous pharmaceutical and cosmetic foam
US86180814 May 201131 Dic 2013Foamix Ltd.Compositions, gels and foams with rheology modulators and uses thereof
US86369827 Ago 200828 Ene 2014Foamix Ltd.Wax foamable vehicle and pharmaceutical compositions thereof
US870310511 Mar 201322 Abr 2014Foamix Ltd.Oleaginous pharmaceutical and cosmetic foam
US870938514 Jul 201029 Abr 2014Foamix Ltd.Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US87220216 Mar 201313 May 2014Foamix Ltd.Foamable carriers
US87412654 Mar 20133 Jun 2014Foamix Ltd.Penetrating pharmaceutical foam
US879563512 May 20105 Ago 2014Foamix Ltd.Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US879569329 Nov 20075 Ago 2014Foamix Ltd.Compositions with modulating agents
US884086928 Abr 200523 Sep 2014Foamix Ltd.Body cavity foams
US88651399 Jul 201421 Oct 2014Foamix Pharmaceuticals Ltd.Topical tetracycline compositions
US88711841 Oct 201028 Oct 2014Foamix Ltd.Topical tetracycline compositions
US89005537 Jun 20102 Dic 2014Foamix Pharmaceuticals Ltd.Oil and liquid silicone foamable carriers and formulations
US890055420 Feb 20122 Dic 2014Foamix Pharmaceuticals Ltd.Foamable composition and uses thereof
US89455161 Oct 20103 Feb 2015Foamix Pharmaceuticals Ltd.Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US899289627 Ago 201431 Mar 2015Foamix Pharmaceuticals Ltd.Topical tetracycline compositions
US90502537 Abr 20149 Jun 2015Foamix Pharmaceuticals Ltd.Oleaginous pharmaceutical and cosmetic foam
US907266727 Ene 20127 Jul 2015Foamix Pharmaceuticals Ltd.Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US91016623 Oct 201311 Ago 2015Foamix Pharmaceuticals Ltd.Compositions with modulating agents
US916191631 Dic 201220 Oct 2015Foamix Pharmaceuticals Ltd.Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US916781327 Ene 201227 Oct 2015Foamix Pharmaceuticals Ltd.Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US92112597 Jun 200615 Dic 2015Foamix Pharmaceuticals Ltd.Antibiotic kit and composition and uses thereof
US92657255 Jul 200723 Feb 2016Foamix Pharmaceuticals Ltd.Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US93207058 Ene 200926 Abr 2016Foamix Pharmaceuticals Ltd.Sensation modifying topical composition foam
US94398571 Dic 200813 Sep 2016Foamix Pharmaceuticals Ltd.Foam containing benzoyl peroxide
US949241222 Abr 201415 Nov 2016Foamix Pharmaceuticals Ltd.Penetrating pharmaceutical foam
US95392084 Feb 201410 Ene 2017Foamix Pharmaceuticals Ltd.Foam prepared from nanoemulsions and uses
US95498982 Oct 201424 Ene 2017Foamix Pharmaceuticals Ltd.Oil and liquid silicone foamable carriers and formulations
US957277517 Sep 201521 Feb 2017Foamix Pharmaceuticals Ltd.Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US96229478 Ene 200918 Abr 2017Foamix Pharmaceuticals Ltd.Foamable composition combining a polar solvent and a hydrophobic carrier
US963640511 Mar 20132 May 2017Foamix Pharmaceuticals Ltd.Foamable vehicle and pharmaceutical compositions thereof
US966229822 Ene 201430 May 2017Foamix Pharmaceuticals Ltd.Wax foamable vehicle and pharmaceutical compositions thereof
US966897211 Mar 20056 Jun 2017Foamix Pharmaceuticals Ltd.Nonsteroidal immunomodulating kit and composition and uses thereof
US967570013 Ene 201513 Jun 2017Foamix Pharmaceuticals Ltd.Topical tetracycline compositions
US968202125 Feb 201420 Jun 2017Foamix Pharmaceuticals Ltd.Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US97136438 May 201425 Jul 2017Foamix Pharmaceuticals Ltd.Foamable carriers
US979556415 Ago 201324 Oct 2017Foamix Pharmaceuticals Ltd.Oil-based foamable carriers and formulations
US20050031547 *28 Abr 200410 Feb 2005Foamix Ltd.Oleaginous pharmaceutical and cosmetic foam
US20080177075 *3 May 200524 Jul 2008Aq+Plc Stephen Mabbott AssociatesCompositions For Progeny Gender Control
US20110045037 *1 Dic 200824 Feb 2011Foamix Ltd.Foam containing benzoyl peroxide
US20110178162 *13 Ene 201121 Jul 2011Medical University Of South CarolinaTargeting pax2 for the induction of defb1-mediated tumor immunity and cancer therapy
EP1495758A2 *7 Ene 200012 Ene 20053M Innovative Properties CompanyFormulations and methods for treatment of mucosal associated conditions with an immune response modifier
EP1495758A3 *7 Ene 200013 Abr 20053M Innovative Properties CompanyFormulations and methods for treatment of mucosal associated conditions with an immune response modifier
WO1987002576A1 *31 Oct 19857 May 1987Kv Pharmaceutical CompanyVaginal delivery systems
WO1998019545A1 *6 Nov 199614 May 1998Reinhard Mark SComposition and method for the treatment of vaginal yeast infections
WO2005105090A1 *3 May 200510 Nov 2005Aq+ PlcCompositions for progeny gender control
Clasificaciones
Clasificación de EE.UU.424/45, 424/94.64, 424/94.3, 424/94.6, 424/94.65, 424/672, 514/967, 514/179, 514/957
Clasificación internacionalA61K9/12, A61K9/00, C09K3/30
Clasificación cooperativaC09K3/30, A61K9/122, Y10S514/967, Y10S514/957, A61K9/0034
Clasificación europeaC09K3/30, A61K9/12B, A61K9/00M8